Article
ANCA-associated vasculitis following secukinumab treatment for psoriasis: Expanding the Spectrum of IL-17A Inhibitor-Related Autoimmunity— A Case Report
2026-06-22
Abstract excerpt
<title>Abstract</title> <p>Background Secukinumab, a fully human monoclonal antibody targeting interleukin-17A, is widely used for the treatment of psoriasis and psoriatic arthritis. Although generally well-tolerated, rare immune-mediated adverse events have been reported with increasing real-world use. We report the first case of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) developing...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 52b1ddc8-6611-5cce-978a-fa9756c15ffb
- DOI
- 10.21203/rs.3.rs-9887892/v1
